---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-002612"
form_type: "8-K"
ticker: "ALGS"
cik: "0001799448"
company_name: "Aligos Therapeutics, Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T19:37:13.833225+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aligos Q1 net loss $34.9M; Phase 2a HERALD study commenced, topline expected Q4 2024

## Summary
- Net loss of $34.9M ($0.22 per share) vs $23.0M ($0.53) in Q1 2023; increase due to non-cash warrant liability charge.
- Cash and investments $112.7M, down from $135.7M at Dec 2023; runway through end of 2025.
- Phase 2a HERALD study (ALG-055009 for MASH) started dosing April 2024; topline data expected Q4 2024.
- Received additional $1.3M NIH grant for pan-coronavirus protease inhibitor ALG-097558; Phase 2 enabling activities underway.

## SEC filing metadata
- accession: 0001171843-24-002612
- form_type: 8-K
- ticker: ALGS
- cik: 0001799448
- company_name: Aligos Therapeutics, Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799448/000117184324002612/0001171843-24-002612-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799448/000117184324002612/f8k_050724.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-002612
- JSON: https://secwatch.observer/filing/0001171843-24-002612.json
- Plain text: https://secwatch.observer/filing/0001171843-24-002612.txt

## Key facts
- Earnings Releases
  Aligos Therapeutics, Inc. reported first quarter 2024 results: net income Net losses for the three months ended March 31, 2024 were $34.9 million, EPS basic and diluted net loss per common share of $(0.22).
  - Period: first quarter 2024
  - Net income: Net losses for the three months ended March 31, 2024 were $34.9 million
  - EPS: basic and diluted net loss per common share of $(0.22)
  - Result: reported results
  source text: Net losses for the three months ended March 31, 2024 were $34.9 million or basic and diluted net loss per common share of $(0.22), compared to net losses of $23.0 million or basic and diluted net loss per common share of $(0.53) for the three months ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1799448/000117184324002612/0001171843-24-002612-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.